Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Muscle and Bone

The effects of palovarotene in patients with fibrodysplasia ossificans progressiva: a plain language summary

This plain language summary from Future Rare Diseases describes the results of the MOVE study, which investigated the drug palovarotene in the treatment of patients with fibrodysplasia ossificans progressiva (FOP).

Read the full article here.

The original article on which this plain language summary is based is titled ‘Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)’ and was published in the Journal of Bone and Mineral Research. Read the original article here.

The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey

The first international fibrodysplasia ossificans progressiva burden of illness survey was carried out to learn more about the physical impact, quality of life impact, and economic impact of the condition on people with FOP and their families. This new plain language summary in Future Rare Diseases discusses the findings from this survey.

Read the full article here.

The original article on which this summary is based is called ‘The Impact of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and their Family Members: Results from an International Burden of Illness Survey’ and was originally published in the journal Expert Review of Pharmacoeconomics & Outcomes Research. The original article can be read here.

Plain language summary of the VOLTAIRE-RA study in patients with moderate-to-severe rheumatoid arthritis

The latest plain language summary of publication from Immunotherapy presents results from the VOLTAIRE-RA study looking at how effective and safe the biosimilar drug BI 695501 is in treating people with rheumatoid arthritis.

Read the summary here.

The original article on which this summary is based is called ‘Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study’ and was originally published in the journal Annals of the Rhematic Diseases. The original article can be read here.

Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study

This plain language summary of publication, co-authored by a patient, a caregiver and a treating physician, includes the patient perspective and help patients with Duchenne muscular dystrophy and their caregivers understand the results of the Cincinnati study.

The Cincinnati study looked at data from 435 males with Duchenne muscular dystrophy who were treated at the Cincinnati Children’s Hospital Medical Center. The study was carried out to further understand the differences between using prednisone and deflazacort in males with DMD.

Read the full article here.

The original article, called ‘Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center’ was also published in the Journal of Comparative Effectiveness Research  and can be read here.

Plain language summary of the long-term effect of ataluren in patients with Duchenne muscular dystrophy

A new article published the Journal of Comparative Effectiveness Research looks at the long-term effect of ataluren in patients with a specific type of genetic mutation leading to Duchenne muscular dystrophy. Looking to help patients understand the study, the authors have published a plain language summary alongside the article.

Read the article and accompanying plain language summary for free here.